UCBMEX:UCBN 85 OCF Margin % is 37.14% as of Dec. 2025, which is 83% above its 10-year median of 20.25. GuruFocus rates MEX:UCBN with a GF Score™ of 85/100 and a GF Value™ of MXN1,417.06. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, UCB ranks better than 89.16% on this metric.
OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. UCB's Cash Flow from Operations for the
six
months ended in Dec. 2025 was MXN33,313 Mil. UCB's Revenue for the
six
months ended in Dec. 2025 was MXN89,691 Mil. Therefore, UCB's OCF Margin % for the quarter that ended in Dec. 2025 was 37.14%.
The historical rank and industry rank for UCB's OCF Margin % or its related term are showing as below:
MEX:UCBN'
s OCF Margin % Range Over the Past 10 Years
Min: 10.3 Med: 20.25 Max: 29.6
Current: 29.45
During the past 13 years, the highest OCF Margin % of UCB was 29.60%. The lowest was 10.30%. And the median was 20.25%.
MEX:UCBN's OCF Margin % is ranked better than 89.16% of 959
companies
in the Biotechnology industry
Industry Median: -66.52
vs MEX:UCBN: 29.45
UCB OCF Margin % Related Terms
UCB OCF Margin % Historical Data
* Premium members only.
The historical data trend for UCB's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:UCBN vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, UCB's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's OCF Margin % distribution charts can be found below:
* The bar in red indicates where UCB's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB (MEX:UCBN) has a OCF Margin % of 37.14% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on UCB and its competitors. This is 83% above median its historical median of 20.25. Over the past decade, UCB's OCF Margin % has ranged from 10.30 to 29.60. According to the industry distribution chart, UCB ranks #104 out of 959 companies in the Biotechnology industry, placing it in the top 10.8%.
Is UCB's OCF Margin % too high?
UCB's current OCF Margin % of 37.14% is 83% above median its 10-year median of 20.25. Over the past 10 years, this metric has ranged from a low of 10.30 to a high of 29.60. Based on the distribution chart, UCB ranks #104 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UCB has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does UCB's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #104 out of 959 companies for OCF Margin %. This places UCB in the top 11% of its industry — outperforming the majority of peers. Historically, UCB's own OCF Margin % has ranged from 10.30 to 29.60 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on UCB and its competitors. UCB's current OCF Margin % is 37.14%, which is 83% above median its own 10-year median of 20.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
UCB (MEX:UCBN) has a current OCF Margin % of 37.14%. The stock's GF Value™ is MXN1,417.06, compared to a current price of MXN1,692.27 — trading 19.4% above its estimated fair value. The current OCF Margin % is 37.14%, which is 83% above median its 10-year median of 20.25. UCB's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For UCB (MEX:UCBN), the current OCF Margin % is 37.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (MEX:UCBN) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be overvalued.
The current stock price of MXN1,692.27 is trading 19.4% above its estimated GF Value™ of MXN1,417.06.
Key valuation signals for MEX:UCBN:
OCF Margin %: 37.14% (83% above median its 10-year median of 20.25)
GF Value™: MXN1,417.06 vs. price of MXN1,692.27 (19.4% above fair value)
No single metric tells the full story. See the MEX:UCBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
85GF Score
Get the complete analysis for MEX:UCBN
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:UCBN has been successfully added to your 
